...and vaginal atrophy (VVA), in postmenopausal women. AMAG expects to launch the drug in mid-2017. Endoceutics...
...million based on AMAG's close of $22.70 on Feb. 13, before the deal was announced. Endoceutics...
...and tissue. Endoceutics Inc. , Quebec City, Quebec AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Waltham, Mass. Business: Genitourinary Shannon Lehnbeuter Intrarosa Endoceutics Inc. AMAG...

...FDA approved an NDA for Intrarosa prasterone from Endoceutics to treat moderate to severe dyspareunia, a...
...to vaginal cells and tissue. Endoceutics Inc. , Quebec City, Quebec Product: Intrarosa prasterone Business: Genitourinary Julian Zhu Intrarosa prasterone Endoceutics Inc....

...offer was more than 6x oversubscribed. Natixis was lead manager and bookrunner. In the U.S., EndoCeutics...

...its dehydroepiandrosterone (DHEA) to treat vaginal atrophy. The company was unavailable for comment. In February, EndoCeutics...

...IPOs last week, while ImaRx refiled after pulling its proposal in December. Hormone therapy company EndoCeutics...
...million. At March 31, ImaRx had $2.8 million in cash. Meanwhile, Canadian hormone therapy company EndoCeutics...
...NASDAQ deal, which is being underwritten by First Albany; Oppenheimer; and Stifel, Nicolaus. At $8, EndoCeutics...

...underwriters. The company originally filed in February to raise up to $75 million. In 2H07, EndoCeutics...

...TBD TBD Ph Ib Helicos 2/28/07 TBD Up to $100.0M TBD TBD Launch 4Q07 (tool) Endoceutics...

...A) Price range Post-$ Status Cosmo Up to 3.4M CHF85.5M ($69.3M) CHF22-CHF28 CHF321.6-CHF409.3M ($260.8-$331.9M) Approved EndoCeutics...

...Hormone therapy company EndoCeutics (Quebec City, Quebec) filed to raise up to $75 million in an...
...in an IPO on NASDAQ underwritten by First Albany; Oppenheimer; and Stifel, Nicolaus. In 2H07, EndoCeutics...